Assessment of the risk and prophylactic treatment of venous thromboembolism in the elderly

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 5-6, 2003, Pages 362-365

  Couturaud, F ^a,b   Lacut, K ^a   Leroyer, C ^a   Mottier, D ^a  

^a Universite de Brest   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Elderly; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; XIMELAGATRAN;

AGE DISTRIBUTION; AMBULATORY CARE; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SCREENING; ELDERLY CARE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; META ANALYSIS; MORTALITY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; HUMANS; RISK ASSESSMENT; VENOUS THROMBOSIS;

EID: 14044265003     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083830     Document Type: Conference Paper

References (23)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:S132-175.
2. Oger E, for the EPI-GETBO Study Group. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost 2000;83:657-660.
3. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
4. Oger E, Bressolette L, Nonent M, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. The TADEUS Project. Thromb Haemost 2002;88:592-597.
5. Heit JA, Silvestein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb haemost 2001;86:452-463.
6. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938.
7. Gatt ME, Paltiel O, Bursztyn M, et al. Is prolonged immobilization a risk factor for symptomatic venous thromboembolsim in elderly bedridden patients? Results of a historical-cohort study. Thromb haemost 2004;91:538-543.
8. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep vein thrombosis in symptomatic outpatients. Arch Intern Med 1994;154:164-168.
9. Landefeld CS, McGuire E, Cohen AM. Clinical findings associated with acute proximal deep vein thrombosis: a basis for quantifying clinical judgement. Am J Med 1990;88:388-392.
10. Petermans J, Zicot M. La pompe musculoveineuse de la personne âgée. J Mal Vasc 1994;19:115-8.
11. Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD. Hypercoagulability in centenarians : the paradox of successful aging. Blood 1995;85:3144-3149.
12. den Heijer JA, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
13. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennkens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997;126:528-531.
14. Oger E, Lacut K, Le Gal G, et al. Is APC resistance a risk factor for venous thromboembolism in patients over 70 years? Thromb Haemost 2002;88:587-591.
15. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-99.
16. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999;159:677-685.
17. Campbell NR, Hull RD, Brant R, et al. Aging and heparin-related bleeding. Arch Intern Med 1996;156:857-860.
18. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical inpatients by a low molecular weight heparin: a randomized double blind trial. Haemostasis 1986;16:159-164.
19. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular weight heparins: a meta-analysis of randomized clinical trials. Thromb haemost 2000;83:14-19.
20. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A Meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2003;163:1833-1839.
21. Dolovitch L, Ginsberg J, Douketis J, Holbrook A. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2001;160:181-188.
22. Eriksson BI, Agnelli G, Cohen AT, et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed oral ximelagatran in comparison with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-296.
23. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest 2003;124:386S-392S.